Grove Bank & Trust’s MaxCyte MXCT Stock Holding History

Grove Bank & Trust’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-67	Closed	-$209	–	659
2023 Q3	$209	Buy	+67	New	+$269	﹤0.01%	735

Other funds holding MXCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grove Bank & Trust's MXCT Position: Q4 2023 in Review

Grove Bank & Trust sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 67 shares — an estimated $209 sold.

Grove Bank & Trust first reported a position in MXCT in Q3 2023 and held it in 1 quarter. The position peaked at $209 in Q3 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

Grove Bank & Trust reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
Grove Bank & Trust sold 67 MaxCyte shares in Q4 2023, an estimated $209.
Grove Bank & Trust first reported a position in MaxCyte in Q3 2023 and held it in 1 quarter.
Grove Bank & Trust's MaxCyte position peaked at $209 in Q3 2023.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.